Patent details

Basic Information

Publication number:

EP2538925

PCT Application Number:

PCT/US/2011/025994

Type:

European Patent Granted for LU

Legal Status:

Revoked

Application number:

EP117072843

PCT Publication Number:

WO/2011/106478

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

APIXABAN FORMULATIONS

French Title of Invention:

FORMULATIONS D'APIXABAN

German Title of Invention:

APIXABAN-FORMULIERUNGEN

SPC Number:

Dates

Filing date:

24/02/2011

Grant date:

16/12/2015

EP Publication Date:

16/12/2015

PCT Publication Date:

01/09/2011

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

02/01/2013

EP B1 Publication Date:

16/12/2015

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

24/02/2031

Renunciation date:

Revocation date:

07/05/2021

Annulment date:

Owner

From:

23/01/2019

 

 

Name:

Bristol-Myers Squibb Holdings Ireland Unlimited Company

Address:

Hinterbergstrasse 16, 6312, Steinhausen, Switzerland (CH)

History of Owners

From:

31/08/2016

To:

23/01/2019

Name:

BRISTOL-MYERS SQUIBB HOLDINGS IRELAND

Address:

HINTERBERGSTRASSE 16, 6312 STEINHAUSEN, Switzerland (CH)

From:

24/02/2011

To:

23/01/2019

Name:

Pfizer Inc.

Address:

235 East 42nd Street, New York, NY 10017, United States (US)

From:

24/02/2011

To:

30/08/2016

Name:

Bristol-Myers Squibb Company

Address:

Route 206 and Province Line Road, Princeton, NJ 08543, United States (US)

Agent

Name:

MARKS & CLERK LLP

From:

14/01/2016

Address:

BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)

To:

Inventor

1

Name:

VEMA-VARAPU Chandra

Address:

United States (US)

2

Name:

FROST Charles

Address:

United States (US)

3

Name:

PATEL Jatin

Address:

United States (US)

4

Name:

JIA Jingpin

Address:

United States (US)

Priority

Priority Number:

308056 P

Priority Date:

25/02/2010

Priority Country:

United States (US)

Classification

Main IPC Class:

A61K 9/28;

Publication

Bulletin

1

Bulletin Heading:

CO

Bulletin edition number:

2019/02

Publication date:

22/02/2019

Description:

Section M : Transfers of property (Art. 53 of the law), change of name and/or address

2

Bulletin Heading:

VRV

Bulletin edition number:

2021/10

Publication date:

01/09/2021

Description:

Section L: Applications for patents or supplementary protection certificates which have been withdrawn or are deemed to have been withdrawn (art. 32, 35.1, 39.5 of the law) Renunciation to a patent or supplementary protection certificate (Art. 72 of the law) Rejected applications for extensions for pediatric use of supplementary protections certificates

European Patent Bulletin

Issue number:

202132

Publication date:

11/08/2021

Description:

Revocation of the European patent

Deed

Change of owner(s)

Change Kind/ Decision Type:

Change of owner(s) name/address

Deed Number:

RC20190000045A

Date Registered:

23/01/2019

Licence Effective Date:

Licence Expiration Date:

Scope of Licence:

Deed Filer:

OFFICE FREYLINGER S.A.

Journal Edition Number:

Text:

Country Code:

Updated Licence Number:

Terminated Licence Number:

Added Owner(s)

Name:

Bristol-Myers Squibb Holdings Ireland Unlimited Company

Address:

Hinterbergstrasse 16, 6312, Steinhausen, Switzerland (CH)

Removed Pledgee

Name:

Address:

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

10/02/2021

Last Annual Fee Paid Number:

11

Last Annual Fee Paid Amount:

148 Euro

Payer:

CPA GLOBAL THE IP PLATFORM

Filing date	Document type	Number of pages
23/01/2019	Request For Change	6
23/01/2019	Outgoing Correspondence	1
12/08/2022	Request For Change	1
02/09/2022	Outgoing Correspondence	56